Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !
Ga offline met de app Player FM !
ValiRx Advances Women's Health and Oncology Pipeline with Focus on Triple-Negative Breast Cancer
Manage episode 460409743 series 2891889
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
ValiRX CEO Dr Mark Eccleston joined Steve Darling from Proactive to discuss the company’s innovative approach to tackling women’s health and oncology challenges. Dr. Eccleston highlighted ValiRx’s collaboration with King’s College London through the Cytolytix joint venture, focusing on developing treatments for triple-negative breast cancer, one of the most aggressive and hard-to-treat forms of the disease. ValiRx adopts a unique model of evaluating and in-licensing promising assets from universities and small pharma companies. This approach enables the company to prioritize science with strong commercial potential, ensuring that innovative discoveries make their way into clinical development. A key asset in development is Cytolytix, a cytolytic peptide that selectively targets cancer cells by creating perforations in their membranes. This novel mechanism not only makes Cytolytix highly specific but also opens the door for its use in combination therapies and immuno-oncology partnerships, potentially revolutionizing cancer treatment. Looking ahead to 2025, Dr. Eccleston outlined plans to advance Cytolytix through preclinical pathways, evaluate three active programs, and expand the pipeline with new assets. In addition, legacy projects such as VAL201 and VAL401 continue to progress, with licensing deals and partnerships, including one with TheoremRx, further solidifying the company’s diverse pipeline. ValiRx remains steadfast in its mission to develop transformative therapies for unmet medical needs, with 2025 poised to be a critical year for clinical advancements and strategic growth. Stay tuned for updates as the company builds momentum in its pursuit of innovative cancer treatments. #proactiveinvestors #valirxplc #aim #val201 #CancerResearch #TripleNegativeBreastCancer #OncologyInnovation #Cytolytix #PharmaPipeline #WomensHealth #CancerTherapy #Biotech #ProactiveInvestors
…
continue reading
605 afleveringen
Manage episode 460409743 series 2891889
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
ValiRX CEO Dr Mark Eccleston joined Steve Darling from Proactive to discuss the company’s innovative approach to tackling women’s health and oncology challenges. Dr. Eccleston highlighted ValiRx’s collaboration with King’s College London through the Cytolytix joint venture, focusing on developing treatments for triple-negative breast cancer, one of the most aggressive and hard-to-treat forms of the disease. ValiRx adopts a unique model of evaluating and in-licensing promising assets from universities and small pharma companies. This approach enables the company to prioritize science with strong commercial potential, ensuring that innovative discoveries make their way into clinical development. A key asset in development is Cytolytix, a cytolytic peptide that selectively targets cancer cells by creating perforations in their membranes. This novel mechanism not only makes Cytolytix highly specific but also opens the door for its use in combination therapies and immuno-oncology partnerships, potentially revolutionizing cancer treatment. Looking ahead to 2025, Dr. Eccleston outlined plans to advance Cytolytix through preclinical pathways, evaluate three active programs, and expand the pipeline with new assets. In addition, legacy projects such as VAL201 and VAL401 continue to progress, with licensing deals and partnerships, including one with TheoremRx, further solidifying the company’s diverse pipeline. ValiRx remains steadfast in its mission to develop transformative therapies for unmet medical needs, with 2025 poised to be a critical year for clinical advancements and strategic growth. Stay tuned for updates as the company builds momentum in its pursuit of innovative cancer treatments. #proactiveinvestors #valirxplc #aim #val201 #CancerResearch #TripleNegativeBreastCancer #OncologyInnovation #Cytolytix #PharmaPipeline #WomensHealth #CancerTherapy #Biotech #ProactiveInvestors
…
continue reading
605 afleveringen
Alle afleveringen
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.